As expected, METTL16 KO suppressed HCC tumor formation and growth (Fig. 2O and Additional file 1: S2A–D), significantly decreased the liver CSC frequency (Fig. 2P) and attenuated the expression of liver CSC markers in vivo (Fig. 2Q). Here, METTL16 is linked to neoplasm.